49 results about "Azacitidine" patented technology

The invention discloses an experiment box for raw material medicine azacitidine, and relates to the technical field of experiment equipment, the experiment box comprises a box body and a sealing device, the left side of the box body is fixedly provided with a temperature control device, the left side of the temperature control device is fixedly provided with a button, the button is electrically connected with the temperature control device, and the front side of the box body is provided with a replacement hole. A replacing plate is slidably mounted on the front side of the box body, a sealing plate slidably penetrates through the right side of the box body, the sealing device comprises a limiting hole, a limiting rod, a limiting spring, a U-shaped rod, a T-shaped plate, a stabilizing plate and a net-shaped frame, and after an experimental container containing azacitidine is placed into the box body, the sealing plate is manually pulled to move leftwards to reset and recover sealing of the box body; when the azacitidine is degraded, moisture in air can enter the box body due to loosening of the sealing plate, so that degradation of azacitidine is accelerated, it can be ensured that the sealing plate is always tightly closed through mistaken touch prevention limitation of the T-shaped plate, and therefore the stability of azacitidine is ensured.

Provided is a combination therapy for an antitumor agent that exhibits a high antitumor effect using a pyridone carboxylic acid derivative.　An antitumor agent characterized by being administered in combination with other antitumor agents, and comprising, as an active ingredient, a compound represented by the formula (1) (in the formula, the wavy line represents the steric configuration being the R configuration or the S configuration) or a salt thereof, wherein the other antitumor agents are one or more types selected from cytarabine, venetoclax, azacitidine, gilteritinib, birabresib, vorinostat, GSK126, MK-8776, AZD7762, rabusertib, dabrafenib, vemurafenib, olaparib, adavosertib, alisertib, decitabine, midostaurin, and AZD5991.

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

The invention discloses a combined treatment medicine for acute myelogenous leukemia. The combined treatment medicine is prepared from vinaclaria, azacitidine and aclarithromycin. The medicine is applied to preparation of an acute myelogenous leukemia cell proliferation inhibitor; the medicine is applied to preparation of an acute myelogenous leukemia cell apoptosis inducer. The three medicines are combined to achieve a synergistic effect: the three medicines have a synergistic anti-tumor effect instead of a simple superposition effect, and a new combined medication mechanism is a result obtained through laboratory research and an initial effect of clinical application. The subsequent consolidation treatment scheme may also be used for part of initially treated patients with acute myelogenous leukemia, which are not suitable for enhanced chemotherapy or intense intense treatment by using targeted drugs, and relapse / refractory patients with acute myelogenous leukemia, and a better treatment scheme can also bring new hope and dawn to more patients.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and chidaridine.

The present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine. In particular, the present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine, which is useful for topical application. The present invention also provides the use of such compositions for medical conditions in the keratinizing and non-keratinizing epithelium / skin, such as the treatment of human papillomavirus (HPV)-related pre-cancerous conditions.

Provided are methods for treating hematologic malignancy, especially AML-MRC, MDS and / or MM. Specifically, provided are methods for treating AML-MRC and MDS with a compound of formula (I) or a pharmaceutically acceptable salt thereof, optionally in combination with at least one additional anti-cancer agent such as 5-azacitidine or cytarabine, and treating MM with a compound of formula (I) or a pharmaceutically acceptable salt thereof, optionally in combination with at least one additional anti-cancer agent such as pomalidomide, thalidomide, lenalidomide, and / or dexamethasone.

The application discloses application of DNA methyltransferase inhibitors in preparation of drugs for treating polycystic kidney disease. Preferably, the DNA methyltransferase inhibitor is decitabine or azacitidine, and the polycystic kidney disease is polycystic kidney disease caused or aggravated by mTOR activation. The application uses Tsc2 knockout mouse embryo fibroblasts MEF and Tsc2 kidney-specific knockout mice, finds that after treatment of the DNA methyltransferase inhibitor decitabine, cell proliferation is inhibited, polycystic kidney disease of the mice is relieved, and kidney function is partially recovered. The application provides a new and effective technical means for treatment of polycystic kidney disease.

The present disclosure relates to a CD47-SIRPα blocking agent of formula (I) stereoisomers thereof, and pharmaceutically acceptable salts, solvates, amides and esters of the compound of formula (I) and stereoisomer thereof and Azacitidine for use in combination with Azacitidine in a method of treating or delaying progression of a disease or a disorder mediated by CD47-SIRPα pathway in a human subject suffering from said disease, such as hematological cancer.

The invention provides a combined pharmaceutical composition of a CDK8 / 19 inhibitor and azacitidine and application of the combined pharmaceutical composition in preparation of antitumor drugs. Particularly, the compound shown in the formula (B) and azacitidine are combined for use, so that a relatively good synergistic effect is shown in a cell proliferation inhibition experiment and an in-vivo tumor model. # imgabs0 #

The invention belongs to the field of novel pharmaceutical preparations, discloses an azacitidine clathrate compound for injection and a preparation method thereof, and particularly relates to an azacitidine clathrate compound freeze-dried preparation with stable properties, the freeze-dried preparation is composed of azacitidine and cyclodextrin, the clathrate compound is formed by adding cyclodextrin, and the freeze-dried preparation is prepared from the azacitidine and the cyclodextrin. According to the azacitidine preparation, the solubility of azacitidine in water is remarkably improved, and the dissolution rate of azacitidine is increased, so that the degradation of azacitidine in water is slowed down, and the stability and safety of azacitidine are improved. The azacitidine clathrate compound for injection is a clear and transparent solution after being redissolved, the subcutaneous injection administration volume is small, the resistance is small, and the clinical compliance is remarkably improved. The product prepared by the technical scheme is stable in quality and good in resolubility, and visible foreign matters and related substances are qualified.

The present disclosure provides methods of treating myeloid malignancies in a subject with a Bcl-2 inhibitor, in particularly 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-((S)-2-(2-isopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzamide or a pharmaceutically acceptable salt thereof, in combination with azacitidine.

A pharmaceutical composition comprising i) a recombinant fusion protein that comprises a mutated SIRPαD1 and a functional IgG1 heavy chain constant region, and ii) azacitidine, for use in treating chronic myelomonocytic leukemia or myelodysplastic syndrome in a subject in need thereof.

The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that binds to CD64, and methods of use in treating acute myeloid leukemia.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and cedazuridine.

Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

The present invention relates to a therapeutic combination of a BTN3A-activating antibody, a Bcl-2 family inhibitor and a demethylating agent, which is useful, inter alia, in the treatment of cancer, in particular hematological malignancies. The present disclosure more particularly relates to the combined use of BTN3A-activating antibodies that activate the cytolytic function of V [gamma] 9V [delta] 2T cells, WiNtural that selectively inhibits the Bcl2 receptor, and a demethylating agent, such as azacitidine, to synergistically and specifically promote the anti-cancer activity of V [gamma] 9V [delta] 2T cells.

Provided herein are methods of treating acute myeloid leukemia (AML) in a subject in need thereof, comprising administering to the subject combinations of Compound 1, or a pharmaceutically acceptable salt thereof, venetoclax, and 5-azacitidine. Also provided herein are methods of inhibiting / overcoming resistance of AML to venetoclax in a subject in need thereof, and / or improving the efficacy of venetoclax in the treatment of AML in a subject in need thereof, comprising administering to the subject combinations of Compound 1, or a pharmaceutically acceptable salt thereof, venetoclax, and 5-azacitidine.

The invention discloses an MDS-AML azacitidine drug-resistant strain, and belongs to the field of drug-resistant strains, the drug-resistant strain is preserved in the China Center for Type Culture Collection, the preservation name is SKM / Aza, and the preservation number is C2024248; the invention also discloses a construction method of the MDS-to-AML azacitidine drug-resistant strain, and the construction method is characterized by comprising the following steps: S1, subculturing an initial SKM1 cell in a cell culture device; s2, adding azacitidine with the drug concentration of 0.1 mu M into the cell culture device, treating for 24 hours, centrifuging at a low speed, changing the liquid and removing the drug to remove dead cells, treating by using the drug with the concentration of 0.1 mu M after the cell state is recovered, observing that the number of dead cells is large, namely removing the drug to recover, and repeating the operation of adding the drug and removing the drug until the cells stably grow under the concentration, so as to obtain the azacitidine. Entering the next stage of drug concentration treatment; and S3, according to the drug treatment concentration, selecting a specific drug concentration for progressive increase treatment.

The present invention relates to a method for detecting azacitidine impurities, and belongs to the technical field of quality control of azacitidine. The present invention provides a method for detecting azacitidine impurities, using liquid chromatography, wherein the stationary phase is uncapped octadecylsilane bonded silica gel, the mobile phase is water-acetonitrile=(85-92):(8-15), v / v, and the ion pair reagent sodium octane sulfonate is added to the water phase. Compared with the prior art, the present detection method has the advantages of being able to simultaneously detect three azacitidine impurities, thereby saving analysis costs, high sensitivity, simple operation, separation and accuracy meeting requirements, good impurity peak symmetry, and greatly reducing the concentration of the test sample, thereby extending the tolerance and service life of the chromatographic column.

The invention relates to a pharmaceutical composition of a 1, 3, 5-triazine derivative, in particular to a pharmaceutical composition of a compound shown as a formula I, a tautomer or pharmaceutically acceptable salt of the compound and azacitidine and medical application of the pharmaceutical composition. # imgabs0 #

The invention belongs to the field of pharmaceutical preparations, and discloses an azacitidine compound for injection and a preparation method thereof, and the freeze-dried preparation comprises azacitidine, povidone and a freeze-dried proppant. The povidone is added to form the compound, so that the solubility of azacitidine in water is remarkably improved, the dissolution rate of azacitidine is increased, degradation of azacitidine in water is slowed down, and the stability and safety of azacitidine are improved. The azacitidine compound for injection is a clear and transparent solution after being redissolved, and is small in injection administration volume and small in resistance, so that the clinical compliance is remarkably improved. The product prepared by the technical scheme is stable in quality and good in resolubility, and visible foreign matters and related substances are qualified.

The present invention provides a compound of Formula (I), or a salt thereof : (I) for use in the treatment or prophylaxis of a cancer, wherein the compound of Formula (I) is administered in combination with Azacitidine and Venetoclax wherein the three compounds are administered simultaneously, sequentially or separately.

The present invention provides a method of treatment and composition for CDC7 inhibitor combinational therapy for treatment of proliferative diseases. In an embodiment, the composition of the present invention comprises a therapeutically effective amount of a combination of a CDC7 inhibitor of the present invention or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents. In an embodiment, the CFC7 inhibitor comprises granaticin B. In an embodiment, the antneoplastic agent comprises azacitidine and venetoclax. The present invention further provides a method of treatment comprising the step of administration to a subject suffering from proliferative disease of any embodiment of the composition of the present invention.

The present disclosure provides methods of using Bcl-2 inhibitors, in particular, 2-((1H-pyrrolo [2, 3-b] pyridin-5-yl) oxy)-N-((4-((((1r, 2r, 2r, 2r, 2r, 2r, 2r, 2r, 2r, 2r, 2r, 2r) The present invention relates to a method for treating myeloid malignancies in a subject by using azacitidine or a pharmaceutically acceptable salt thereof, and more particularly, to a method for treating myeloid malignancies in a subject by using azacitidine or a pharmaceutically acceptable salt thereof in combination with azacitidine.

The present invention discloses an experimental box for azacitidine, a raw material drug, and relates to the technical field of experimental equipment. The box comprises a box body and a sealing device, wherein a temperature control device is fixedly installed on the left side of the box body, a button is fixedly installed on the left side of the temperature control device, and the button is electrically connected to the temperature control device. A replacement hole is opened on the front side of the box body, a replacement plate is slidably installed on the front side of the box body, and a sealing plate is slidably penetrated on the right side of the box body, wherein the sealing device comprises a limiting hole, a limiting rod, a limiting spring, a U-shaped rod, a T-shaped plate, a stabilizing plate and a mesh frame. After an experimental container containing azacitidine is placed in the box body, the sealing plate is manually pulled to move to the left to reset and restore the sealing of the box body. Loosening of the sealing plate will cause moisture in the air to enter the box body, thereby accelerating the degradation of azacitidine. The anti-mistouch restriction of the T-shaped plate can ensure that the sealing plate is always tightly closed, thereby ensuring the stability of azacitidine.

1. Name of the product of this design: Packaging box (azacitidine for injection). 2. Purpose of this design product: The design product is used for packaging of medicines. 3. The design key point of this appearance design product lies in the combination of shape and pattern. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The invention provides a light-triggered epigenetic reprogramming engineering microorganism with a CT (Computed Tomography) imaging function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The engineering microbial strain provided by the invention is prepared by coupling Mo1.33C nanosheets and azacitidine independently or jointly as active pharmaceutical ingredients and facultative anaerobic escherichia coli capable of realizing precise delivery of tumor sites as a carrier. An effective delivery platform of a DNMT1 inhibitor and / or iMxene is established, epigenetic immunity is activated, a way is laid for epigenetic regulation in solid tumor treatment, meanwhile, Mo1. 33C is a reagent for CT imaging and infrared imaging and can be used for multi-mode diagnosis and PTT and epigenetic treatment, and an integrated diagnosis and treatment nano platform is created.

A method of treating chronic myelomonocytic leukemia or myelodysplastic syndrome in a subject in need thereof, comprising the steps of: (a) administering intravenously to the subject for the chronic myelomonocytic leukemia about 2.0 mg / kg body weight per day of a recombinant fusion protein of SEQ ID NO: 1 in the form of a composition comprising a pharmaceutically acceptable excipient and the recombinant fusion protein, (b) about 65 minutes to about 75 minutes after completing the administering of step (a), administering subcutaneously to the subject about 75 mg / m2 of azacitidine, and (c) after steps (a) and (b), repeating step (a) once weekly, and administering subcutaneously to the subject about 75 mg / m2 of azacitidine once daily, wherein on the days that the subject is also having step (a) repeated, the azacitidine is administered about 65 minutes to about 75 minutes after completing the repeated administering of step (a).